002603 Shijiazhuang Yiling Pharmaceutical
- 19.08
- -0.09-0.47%
Shijiazhuang Yiling Pharmaceutical News
China Merchants Securities: The 24Q1 Chinese medicine sector has steadily overcome high base pressure, and profit levels and dividends have improved markedly
The traditional Chinese medicine industry was slightly under pressure due to high base pressure in the short term, but the level of profit and dividends performed well. In the context of policies encouraging the inheritance, innovation and development of traditional Chinese medicine, along with the reform of state-owned enterprises and the implementation of catalytic events such as the basic drug catalogue, the traditional Chinese medicine sector is still cost-effective.
Eling Pharmaceutical (002603.SZ): Recertified as a high-tech enterprise
On May 10, Gelonghui Pharmaceutical (002603.SZ) announced that it has recently received the “High-tech Enterprise Certificate” jointly issued by the Hebei Provincial Department of Science and Technology, the Hebei Provincial Department of Finance, and the Hebei Provincial Taxation Bureau of the State Administration of Taxation. The company has already made tax returns and prepayments according to the 15% corporate income tax rate in 2023, so obtaining a high-tech enterprise certificate this time will not affect the company's relevant financial data for 2023.
These Analysts Just Made An Incredible Downgrade To Their Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) EPS Forecasts
The analysts covering Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for
Why Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Shaky Earnings Are Just The Beginning Of Its Problems
A lackluster earnings announcement from Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) last week didn't sink the stock price. Our analysis suggests that along with soft profit numbers, in
Eling Pharmaceutical (002603.SZ) reported 2023 annual results, with net profit of 1,352 billion yuan, a year-on-year decrease of 42.76%
According to the Zhitong Finance App, Eling Pharmaceutical (002603.SZ) released its 2023 annual report, with revenue of 10.318 billion yuan, a year-on-year decrease of 17.67%. Net profit attributable to shareholders of listed companies was 1,352 billion yuan, a year-on-year decrease of 42.76%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,244 billion yuan, a year-on-year decrease of 45.58%. The basic income per share is 0.8095 yuan, a cash dividend of 3.00 yuan (tax included) is distributed to all shareholders for every 10 shares, 0 bonus shares (tax included), and no share capital is transferred from the Provident Fund.
Is Weakness In Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) recent performance, when its stock has declined 13% over the past three months. But if you pay close att
Eling Pharmaceutical (002603.SZ): Jinlida granules have not yet conducted clinical studies on “weight loss” indications
Gelonghui, April 10 | Eling Pharmaceutical (002603.SZ) said on an interactive platform that Jinlida granules have not conducted clinical research on “weight loss” indications. In 2015, the “Randomized, double-blind, placebo-controlled, multicenter clinical trial of efficacy and safety of metformin monotherapy patients with type 2 diabetes after administration of Jinrida granules” led by the Chinese Academy of Traditional Chinese Medicine Guanganmen Hospital and the University of Chicago Chinese Medicine Research Office, was published in “Plos One” magazine. The results showed that in diet control, exercise therapy, and dimethylbisubin
Individual Investors Invested in Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Copped the Brunt of Last Week's CN¥2.1b Market Cap Decline
Key Insights The considerable ownership by individual investors in Shijiazhuang Yiling Pharmaceutical indicates that they collectively have a greater say in management and business strategy 52% of t
Does Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Sometimes these stories can cloud the min
Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) 25% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. Long
Benign Growth For Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Underpins Its Share Price
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 35x, you may consider Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) as a highly attractive inves
Individual Investors Among Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Largest Stockholders and Were Hit After Last Week's 3.2% Price Drop
Key Insights Significant control over Shijiazhuang Yiling Pharmaceutical by individual investors implies that the general public has more power to influence management and governance-related decisions
Here's Why We Think Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Sometimes these stories can cloud the minds
Yiling Pharmaceutical (002603.SZ): New drug registration application for Xinqi Tongnose tablets accepted
Yiling Pharmaceutical (002603.SZ) announced that Beijing Yiling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (“Beijing...
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%
Shijiazhuang Yiling Pharmaceutical (SHE:002603) received approval from China's National Medical Products Administration to convert Lianhua Qingke tablets into an over-the-counter drug. The traditional
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules
Shijiazhuang Yiling Pharmaceutical (SHE:002603) will conduct clinical trials into traditional Chinese medicine huoxia cold granules after obtaining the approval of China's National Medical Products Ad
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) recent performance, when its stock has declined 5.1% over the past month. However, stock prices are usua
[BT Financial Report Instantaneous Analysis] Yiling Pharmaceutical's 2023 Three-Quarter Report: Steady Growth in Performance, Significant Decline in Net Cash Flow
This financial report was announced on 2023-10-27 18:59:08 Eling Pharmaceutical (stock code: 002603) is a pharmaceutical industry company focusing on the field of traditional Chinese medicine. In recent years, China has vigorously developed the traditional Chinese medicine business and promoted the reform and development of traditional Chinese medicine. Ling Pharmaceutical has responded positively to national policies, is committed to R&D and innovation in traditional Chinese medicine, and promoted the upgrading and development of the traditional Chinese medicine industry. In terms of assets and liabilities, Eling Pharmaceutical's total assets for the third quarter of 2023 were 17.435 billion yuan, up from 16.338 billion yuan at the end of the previous year. Total liabilities were $5.587 billion, slightly higher than
Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Sheds 3.2% This Week, as Yearly Returns Fall More in Line With Earnings Growth
It hasn't been the best quarter for Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) shareholders, since the share price has fallen 11% in that time. But that doesn't change the fact that
Analysis
Price Target
No Data
